Cancer immunotherapy has emerged as a powerful treatment option characterized by durable remissions and tolerable side effects.
In recent years, an unprecedented number of immune-based therapeutic modalities have been approved in the first- and second-line as well as in the adjuvant setting across a growing number of malignancies. This influx of approvals has created a need to stay current on the latest recommendations for the appropriate application of immunotherapy.
Cancer Immunotherapy CONNECT, powered by SITC is your hub to participate in live and online educational opportunities to learn more about integrating cancer immunotherapy into your practice. Download a variety of resources in our library and connect with other clinicians in our online Community to learn more about the latest approvals, patient selection criteria, relevant biomarkers and immune-related adverse events.